Views of Wall Street’s Leading Experts on Oramed Pharmaceuticals Inc.

With 0.59 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.98 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $4.5100 whereas the lowest price it dropped to was $4.2150. The 52-week range on ORMP shows that it touched its highest point at $13.73 and its lowest point at $1.81 during that stretch. It currently has a 1-year price target of $13.27. Beta for the stock currently stands at 1.69.

Top 5 EV Tech Stocks to Buy for 2023

According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.

Click Here to Download the FREE Report.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ORMP was up-trending over the past week, with a rise of 23.14%, but this was up by 104.11% over a month. Three-month performance surged to 114.90% while six-month performance fell -42.77%. The stock lost -2.61% in the past year, while it has lost -62.84% so far this year. A look at the trailing 12-month EPS for ORMP yields -0.75 with Next year EPS estimates of -0.49. For the next quarter, that number is -0.13. This implies an EPS growth rate of -198.20% for this year and 3.90% for next year.

Float and Shares Shorts:

At present, 40.04 million ORMP shares are outstanding with a float of 37.06 million shares on hand for trading. On Apr 27, 2023, short shares totaled 0.52 million, which was 1.31% higher than short shares on Mar 30, 2023. In addition to Mr. Nadav Kidron Esq. as the firm’s Pres, CEO & Exec. Chairman, Mr. David Silberman CPA serves as its CFO & Treasurer.

Institutional Ownership:

Through their ownership of 12.64% of ORMP’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 9.45% of ORMP, in contrast to 3.05% held by mutual funds. Shares owned by individuals account for 19.72%. As the largest shareholder in ORMP with 3.41% of the stake, BML Capital Management LLC holds 1,355,925 shares worth 1,355,925. A second-largest stockholder of ORMP, Two Sigma Investments LP, holds 506,255 shares, controlling over 1.27% of the firm’s shares. Two Sigma Advisers LP is the third largest shareholder in ORMP, holding 444,900 shares or 1.12% stake. With a 0.37% stake in ORMP, the Harel Sal is the largest stakeholder. A total of 145,053 shares are owned by the mutual fund manager. The MTF SAL, which owns about 0.29% of ORMP stock, is the second-largest Mutual Fund holder. It holds 116,383 shares valued at 0.26 million. iShares Tr. – Micro Cap ETF holds 0.21% of the stake in ORMP, owning 82,698 shares worth 0.19 million.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Mar 30, 2023, ORMP reported revenue of $674.00k and operating income of -$11.42M. The EBITDA in the recently reported quarter was -$11.40M and diluted EPS was -$0.27.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ORMP since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With ORMP analysts setting a high price target of $2.00 and a low target of $2.00, the average target price over the next 12 months is $2.00. Based on these targets, ORMP could drop -55.26% to reach the target high and fall by -55.26% to reach the target low. Reaching the average price target will result in a decline of -55.26% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.

Summary of Insider Activity:

Insiders traded ORMP stock several times over the past three months with 15 Buys and 1 Sells. In these transactions, 1,093,309 shares were bought while 100,000 shares were sold. The number of buy transactions has increased to 27 while that of sell transactions has risen to 6 over the past year. The total number of shares bought during that period was 1,568,309 while 160,260 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *